Search Results 1651-1660 of 21936 for Inhibition
... inhibitor (BTKi) treatment or have been deemed ineligible for BTKi therapy. ... inhibitors which cannot be discontinued. Note: Other protocol defined ...
... inhibitors sirolimus or everolimus as part of their clinical care. ... inhibitors treatments, have been unsuccessful or not well tolerated, and the patient ...
Receiving cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening or Janus kinase inhibitor therapy within 4 weeks of ...
Previous therapy with an telangiectasia and rad3 related protein inhibitor. ... Concomitant use of known strong CYP 3A inhibitors and inducers. Eligibility ...
... Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 Jul; 163 (1):204-221 Epub 2022 Apr ...
... inhibitors, CDK4/6 inhibitors, TDM-1, pertuzumab, or immunotherapy). (Participants may still be taking adjuvant therapy with trastuzumab or adjuvant ...
Use of a monoamine oxidase inhibitor (MAOI) or other antidepressants must be ... No concomitant treatment with strong CYP1A2 and CYP2D6 inhibitors; ...
Prior treatment with CYP17 inhibitor (e.g., ketoconazole, abiraterone acetate, galeterone) or next generation androgen receptor antagonist including apalutamide ...
For patients on phosphodiesterase type-5 inhibitors ... Treatment with strong cytochrome P450 (CYP) 3A4 inducers or inhibitors within 4 weeks prior to Visit 2 ...
... inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!